TCV Trust & Wealth Management Inc. Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

TCV Trust & Wealth Management Inc. boosted its position in Pfizer Inc. (NYSE:PFE) by 1.3% during the third quarter, Holdings Channel.com reports. The fund owned 34,098 shares of the biopharmaceutical company’s stock after acquiring an additional 450 shares during the period. TCV Trust & Wealth Management Inc.’s holdings in Pfizer were worth $987,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. Olistico Wealth LLC purchased a new position in Pfizer during the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $29,000. Quarry LP purchased a new position in shares of Pfizer during the second quarter valued at approximately $31,000. Financial Connections Group Inc. purchased a new position in shares of Pfizer during the second quarter valued at approximately $34,000. Finally, ESL Trust Services LLC bought a new position in shares of Pfizer during the first quarter valued at approximately $37,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on PFE shares. Barclays boosted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Sanford C. Bernstein started coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Stock Down 0.7 %

Shares of Pfizer stock opened at $28.45 on Friday. The company has a 50-day simple moving average of $29.08 and a two-hundred day simple moving average of $28.51. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The stock has a market capitalization of $161.21 billion, a PE ratio of -474.17, a price-to-earnings-growth ratio of 1.01 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period last year, the company earned $0.67 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.67 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.91%. Pfizer’s dividend payout ratio (DPR) is currently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.